1011 — China NT Pharma Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$55.46m
- HK$427.02m
- CNY7.37m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | — |
Source: | ARS | ARS | ARS | ARS | |
Standards: | HKAS | HKAS | HKAS | — | — |
Status: | Final | Final | Final | Final | fx Preliminary |
Net Income/Starting Line | -583 | -200 | -149 | -54.3 | — |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 599 | 66.6 | 64.7 | 82.7 | — |
Discontinued Operations | |||||
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.67 | 135 | -93 | -13.2 | — |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 47.8 | 26.2 | -135 | 36.2 | — |
Capital Expenditures | -87.2 | -23.8 | -0.646 | -4.49 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -120 | 619 | 258 | 9.02 | — |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -207 | 596 | 258 | 4.53 | — |
Financing Cash Flow Items | -99.2 | -66.1 | -43.3 | -19.7 | — |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 101 | -624 | -125 | -46.7 | — |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -59.6 | -20.4 | 1.61 | -2.45 | — |